1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

Slides:

Advertisements

Similar presentations

Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):

Advertisements

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

Monitoring Safety of Rotavirus Vaccines David Martin, MD, MPH CBER Office of Biostatistics and Epidemiology, FDA For presentation at the Vaccines and Related.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Orlistat Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.

Available Types of National Drug Use Data DSARM Advisory Committee Meeting Silver Spring, Maryland May 18, 2005 Judy Staffa, PhD, RPh, Epidemiology Team.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post Exclusivity Adverse Event Review: Topotecan Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M. D

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD,

Regulatory History of Aspirin Cardiovascular and Renal Drugs Advisory Committee Meeting Michelle M. Jackson, Ph.D. Division of Over-The-Counter Drug Products.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

1 One Year Post-Exclusivity Adverse Event Review: Norgestimate/ethinyl estradiol Pediatric Advisory Committee Meeting June 29, 2005 Hari Cheryl Sachs,

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Food and Drug Administration Center for Drug Evaluation and Research Lessons Learned from Growth Studies with Orally Inhaled and Intranasal Corticosteroids.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

1 One Year Post-Exclusivity Adverse Event Review: Rosiglitazone Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

Endocrinologic & Metabolic Drugs Advisory Committee Meeting

1 One Year Post Exclusivity Adverse Event Review: Sibutramine Pediatric Advisory Committee Meeting March 22, 2006 Hari Cheryl Sachs, MD, FAAP Medical Officer.

Risk Assessment / Risk Management of EXANTA ® (ximelagatran) Liver Injury Kate Gelperin, M.D., M.P.H. Medical Officer Division of Drug Risk Evaluation.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Opiate Analgesic Use in Pediatric Patients Bob Rappaport, M.D. Deputy Division Director Division of Anesthetic, Critical Care and Addiction Drug Products,

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

Manufacturer: AstraZeneca FDA Approval Date: December 22, 2015

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

Department of Health and Human Services Center for Drug Evaluation and Research 1 Issues in Projecting Increased Risk of Cardiovascular Events to the Exposed.

Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4

Available Types of National Drug Use Data

Presentation transcript:

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29, 2005 Solomon Iyasu, M.D., M.P.H. Acting Deputy Director Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration

2 Abbreviated Presentations of BPCA-mandated Adverse Event Review No new safety signals –Paricalcitol (Zemplar ® ) –Zolmitriptan (Zomig ® ) –Dorzolamide (Trusopt ® ) –Leflunomide (Arava ® )

3 Background Drug Information Drug: Zemplar ® (paricalcitol) Therapeutic Category: Vitamin D Analog Sponsor: Abbott Laboratories Indication: Prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure Original Market Approval: April 17, 1998 Pediatric Exclusivity Granted: December 8, 2003

4Summary: No pediatric adverse events were reported through AERS from market approval through January 2005No pediatric adverse events were reported through AERS from market approval through January 2005 It is estimated that approximately 1000 pediatric dialysis patients may be exposed to paracalcitol. 1It is estimated that approximately 1000 pediatric dialysis patients may be exposed to paracalcitol. 1 Safety and effectiveness were examined in a 12 week trial in pediatric patients with end stage renal disease on hemodialysis (described in labeling)Safety and effectiveness were examined in a 12 week trial in pediatric patients with end stage renal disease on hemodialysis (described in labeling) No patients in the trial developed hypercalcemiaNo patients in the trial developed hypercalcemia 1 U.S. Renal Data System Annual Data Report: Atlas of End-Stage Renal Disease in the United States [on-line]. Available from URL:

5 Background Drug Information Drug: Zomig ® Tablets and Zomig-ZMT ® Orally Disintegrating Tablets (zolmitriptan) Therapeutic Category: Selective 5-hydroxytryptamine receptor agonist Sponsor: AstraZeneca Indication: Acute treatment of migraine with or without aura in adults. Not recommended for pediatric use (information from exclusivity studies in the label) Original Market Approval: November 25, 1997 Pediatric Exclusivity Granted: December 18, 2003

6 Zomig ® ( Zolmitriptan ) Pediatric patients accounted for less than 2% of all claims for Zomig ® oral tablets and 5% of all claims for Zomig- ZMT ®1Pediatric patients accounted for less than 2% of all claims for Zomig ® oral tablets and 5% of all claims for Zomig- ZMT ®1 Two pediatric adverse event reports identified during the one year post-exclusivity period:Two pediatric adverse event reports identified during the one year post-exclusivity period: –Accidental ingestion of 2.5 mg Zomig ® by a toddler. Hospitalized for observation, no adverse reaction noted. –Adolescent with partial seizure after taking Zomig ®. Patient had history of seizures following astrocytoma removal that were not being treated. Partial seizures are unlabeled but unclear if due to drug or underlying pathology. 1 Caremark Dimension Rx™, Jan Dec 2004, Data extracted Jan 2005

7 Pediatric Adverse Event Reports: November 25, 1997 – January 18, 2005 All pediatric reports: 24* –Deaths: 2 reports, both of the same patient with an intentional overdose of Imitrex ®, Zomig ® and Sudafed ® –Unlabeled events: dyspnea, drug ineffective, lethargy, accidental exposure, accidental overdose, brain edema**, pupil fixed** No new concerning unlabeled safety signals identified in pediatric adverse events reported through AERS from market approval through January 2005 Underlined = Unlabeled events in Zomig ® and Zomig-ZMT ® *Includes duplicate reports ** Only noted in the intentional overdose

8 Background Drug Information Drug: Trusopt ® (dorzolamide ophthalmic solution) Therapeutic Category: carbonic anhydrase inhibitor Sponsor: Merck Indication: Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma Original Market Approval: December 9, 1994 Pediatric Exclusivity Granted: January 5, 2004

9 Dorzolamide Ophthalmic Solution (Trusopt ® ) Minimal use in Pediatrics: 0.5% (472/92,688) prescription claims for dorzolamide hydrochloride, ages 1-16 years 1Minimal use in Pediatrics: 0.5% (472/92,688) prescription claims for dorzolamide hydrochloride, ages 1-16 years 1 No adverse events reported during the 1-year post-exclusivity periodNo adverse events reported during the 1-year post-exclusivity period Conclusion: No new safety signal foundConclusion: No new safety signal found 1 Caremark Dimension Rx™, Feb Jan 2005, Data extracted Mar 2005

10 Background Drug Information Drug: Arava ® (leflunomide) Therapeutic Category: immunomodulator (pyrimidine synthesis inhibitor) Sponsor: Aventis Indication: Treatment of rheumatoid arthritis in adults: -to reduce signs and symptoms -to inhibit structural damage as evidenced by X-ray erosions and joint space narrowing -to improve physical function Original Market Approval: September 10, 1998 Pediatric Exclusivity Granted: November 10, 2003

11 Leflunomide (Arava ® ) No pediatric indication because failed to win on primary endpointNo pediatric indication because failed to win on primary endpoint Superiority design against high dose methotrexateSuperiority design against high dose methotrexate Leflunomide showed activity over historical baselineLeflunomide showed activity over historical baseline JRA difficult disease/ treated by specialistsJRA difficult disease/ treated by specialists Details/results of trial in PK section of labelingDetails/results of trial in PK section of labeling

12 Leflunomide (Arava ® ) Minimal use in pediatrics: 0.1% (105/74,574) prescription claims for leflunomide, ages 1-16 years 1Minimal use in pediatrics: 0.1% (105/74,574) prescription claims for leflunomide, ages 1-16 years 1 Two adverse event reports for the 1-year post- exclusivity period:Two adverse event reports for the 1-year post- exclusivity period: -transient elevation of liver enzymes (labeled event), recovered -liver failure after an intentional overdose of acetaminophen while on leflunomide, resolved Conclusion: No new safety signal foundConclusion: No new safety signal found 1 Caremark Dimension Rx™, Dec Nov 2004, Data extracted Jan 2005

13 Conclusion This completes the one-year post- exclusivity AE monitoring as mandated by BPCA.This completes the one-year post- exclusivity AE monitoring as mandated by BPCA. FDA recommends routine monitoring of AEs for Zemplar ®, Zomig ®, Trusopt ® and Arava ® in all populations.FDA recommends routine monitoring of AEs for Zemplar ®, Zomig ®, Trusopt ® and Arava ® in all populations. Does the Advisory Committee concur?Does the Advisory Committee concur?

14AcknowledgementsODS Mark AviganMark Avigan Renan BonnelRenan Bonnel Gerald Dal PanGerald Dal Pan Michael EvansMichael Evans Andrea FeightAndrea Feight Laura GovernaleLaura Governale David MoenyDavid Moeny Carol PamerCarol Pamer Sonny SainiSonny Saini Judy StaffaJudy Staffa Kendra WorthyKendra Worthy OND Eric Bastings Eric Bastings Wiley Chambers Wiley Chambers Lana Chen Lana Chen Eric Colman Eric Colman Jane Dean Jane Dean Rhea Lloyd Rhea Lloyd Patricia Madara Patricia Madara Theresa Podruchny Theresa Podruchny Allison Rodgers Allison Rodgers Carolyn Yancey Carolyn Yancey